Inari Medical (NASDAQ: NARI) continues to ride on the success of its ClotTriever and FlowTriever products available for treating venous thromboembolism (VTE). The adoption of these products is rising on the back of their features, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the unique characteristics of specific disease states with better effectiveness. Apart from the efficacy of the products, an attractive procedural reimbursement is also fueling their adoption. The stock carries a Zacks Rank #3 (Hold) at present. ClotTriever products help in the removal of clots from peripheral blood vessels in patients suffering from deep vein thrombosis (DVT). Meanwhile, its FlowTriever product is the first thrombectomy system, approved for the treatment of pulmonary embolism. Inari registered revenues of $143.2 million in the first quarter, up 23.3% year over year. During the reported quarter, NARI witnessed growth in revenues for its global VTE business on the back of commercial expansion and market development. Backed by supportive clinical data and attractive reimbursement, Inari's VTE excellence sales program is driving deeper adoption within the existing U.S. account base as well as adding new accounts. Meanwhile, the company is also focused on expanding in international markets. According to management, Inari Medical saw record cases and revenue generation outside the United States in the ...